Enhanced expression of an α2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor

Journal of Clinical Microbiology

Volumn 43, Issue 8, 2005, Pages 4139-4146

  Hatakeyama, Shuji ^a,b,c   Sakai Tagawa, Yuko ^a,b   Kiso, Maki ^a,b   Goto, Hideo ^a,b   Kawakami, Chiharu ^d   Mitamura, Keiko ^e   Sugaya, Norio ^f   Suzuki, Yasuo ^b,g   Kawaoka, Yoshihiro ^a,b,h  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Yokohama City Institute of Health   (Japan)

^e KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^f Keiyu Hospital   (Japan)

^g UNIVERSITY OF SHIZUOKA   (Japan)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDE ALPHA2,6 SIALYLTRANSFERASE I; OSELTAMIVIR; SIALIC ACID DERIVATIVE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; ANTIVIRUS AGENT; ENZYME INHIBITOR; N ACETYLNEURAMINIC ACID; SIALIDASE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; CELL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; GENE EXPRESSION; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS GENE; VIRUS ISOLATION; ANIMAL; DOG; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; ORTHOMYXOVIRUS;

HUMAN INFLUENZA VIRUS; INFLUENZA VIRUS;

ACETAMIDES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; ENZYME INHIBITORS; HUMANS; N-ACETYLNEURAMINIC ACID; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OSELTAMIVIR;

EID: 23744452330     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.8.4139-4146.2005     Document Type: Article

References (32)

1. Barnett, J. M., A. Cadman, D. Gor, M. Dempsey, M. Walters, A. Candlin, M. Tisdale, P. J. Morley, I. J. Owens, R. J. Fenton, A. P. Lewis, E. C. Claas, G. F. Rimmelzwaan, R. De Groot, and A. D. Osterhaus. 2000. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob. Agents Chemother. 44:78-87.
2. Carr, J., J. Ives, L. Kelly, R. Lambkin, J. Oxford, D. Mendel, L. Tai, and N. Roberts. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 54:79-88.
3. Centers for Disease Control and Prevention. 2004. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep. 53:1-40.
4. Connor, R. J., Y. Kawaoka, R. G. Webster, and J. C. Paulson. 1994. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205:17-23.
5. Couceiro, J. N., J. C. Paulson, and L. G. Baum. 1993. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 29:155-165.
6. Gubareva, L. V., M. J. Robinson, R. C. Bethell, and R. G. Webster. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 71:3385-3390.
7. Gubareva, L. V., M. N. Matrosovich, M. K. Brenner, R. C. Bethell, and R. G. Webster. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178:1257-1262.
8. Gubareva, L. V., L. Kaiser, M. N. Matrosovich, Y. Soo-Hoo, and F. G. Hayden. 2001. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183:523-531.
9. Hayden, F. G., K. M. Cote, and R. G. Douglas, Jr. 1980. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob. Agents Chemother. 17:865-870.
10. Herlocher, M. L., J. Carr, J. Ives, S. Elias, R. Truscon, N. Roberts, and A. S. Monto. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111.
11. Herlocher, M. L., R. Truscon, S. Elias, H. L. Yen, N. A. Roberts, S. E. Ohmit, and A. S. Monto. 2004. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis. 190:1627-1630.
12. Hidari, K., N. Horie, T. Murata, D. Miyamoto, T. Suzuki, T. Usui, and Y. Suzuki. 2005. Purification and characterization of soluble recombinant ST6Gal I expressed in Escherichia coli: application of the recombinant enzyme for generation of a glycoprotein with anti-influenza virus activity. Glycoconj. J. 22:1-11.
13. Ito, T., Y. Suzuki, A. Takada, A. Kawamoto, K. Otsuki, H. Masuda, M. Yamada, T. Suzuki, H. Kida, and Y. Kawaoka. 1997. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J. Virol. 71:3357-3362.
14. Ito, T., J. N. Couceiro, S. Kelm, L. G. Baum, S. Krauss, M. R. Castrucci, I. Donatelli, H. Kida, J. C. Paulson, R. G. Webster, and Y. Kawaoka. 1998. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J. Virol. 72:7367-7373.
15. Kiso, M., K. Mitamura, Y. Sakai-Tagawa, K, Shiraishi, C. Kawakami, K. Kimura, F. G. Hayden, N. Sugaya, and Y. Kawaoka. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765.
16. Kobasa, D., S. Kodihalli, M. Luo, M. R. Castrucci, I. Donatelli, Y. Suzuki, T. Suzuki, and Y. Kawaoka. 1999. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J. Virol. 73:6743-6751.
17. Liu, C., M. C. Eichelberger, R. W. Compans, and G. M. Air. 1995. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol. 69:1099-1106.
18. Matrosovich, M., T. Matrosovich, J. Carr, N. A. Roberts, and H. D. Klenk. 2003. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77:8418-8425.
19. Matrosovich, M. N., T. Y. Matrosovich, T. Gray, N. A. Roberts, and H. D. Klenk. 2004. Hum. and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl. Acad. Sci. USA 101:4620-4624.
20. McKimm-Breschkin, J. L., T. J. Blick, A. Sahasrabudhe, T. Tiong, D. Marshall, G. J. Hart, R. C. Bethell, and C. R. Penn. 1996. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 40:40-46.
21. McKimm-Breschkin, J. L., M. McDonald, T. J. Blick, and P. M. Colman. 1996. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 225:240-242.
22. McKimm-Breschkin, J. L. 2000. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res. 47:1-17.
23. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.
24. Palese, P., K. Tobita, M. Ueda, and R. W. Compans. 1974. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61:397-410.
25. Rogers, G. N., and J. C. Paulson. 1983. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 127:361-373.
26. Thompson, W. W., D. K. Shay, E. Weintraub, L. Brammer, C. B. Bridges, N. J. Cox, and K. Fukuda. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340.
27. Tisdale, M. 2000. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10:45-55.
28. Tsuji, S. 1996. Molecular cloning and functional analysis of sialyltransferases. J. Biochem. 120:1-13.
29. Weinstein, J., U. de Souza-e-Silva, and J. C. Paulson. 1982. Purification of a Galβ1-4GlcNAcα2-6 sialyltransferase and a Galβ1-3(4) GlcNAcα2-3 sialyltransferase to homogeneity from rat liver. J. Biol. Chem. 257:13835-13844.
30. Woods, J. M., R. C. Bethell, J. A. Coates, N. Healy, S. A. Hiscox, B. A. Pearson, D. M. Ryan, J. Ticehurst, J. Tilling, S. M. Walcott, and C. R. Penn. 1993. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37:1473-1479.
31. World Health Organization. Accessed 5 October 2004. Global Influenza Programme manual on animal influenza diagnosis and surveillance, http: //www.who.int/emc-documents/influenza/docs/animalinfluenza/HTML/.
32. Zambon, M., and F. G. Hayden, 2001. Global Neuraminidase Inhibitor Susceptibility Network. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49:147-156.